BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease

BD completes iliac cohort enrollment in AGILITY study evaluating Revello stent for peripheral artery disease

Medical Economics serves as the connection to Physician Practice Management, featuring financial strategies, business insights, and expert interviews.

BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease

FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a…

BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease - Life Sciences British Columbia

FRANKLIN LAKES, N.J. - BD announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption

BD Completes Enrollment of Iliac Cohort in AGILITY IDE Study of Revello Covered Stent

November 4, 2025— BD announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY investigational device exemption (IDE) study, which is evaluating the Revello vascular covered stent for the treatment of peripheral artery disease (PAD). The enrollment milestone announcement was made in conjunction with a late-breaking clinical trial presentation at VIVA25 by Sean Lyden, MD, Chairman of the Department of Vascular Surgery at…